The Conversation (0)
All dollar amounts reflected in Canadian dollars unless otherwise stated.
Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended September 30, 2025 ("Q3 2025") and provided an update on recent corporate developments.
Q3 2025 Financial Highlights
- Reported a net loss of $1,781,757 .
- Research and development (R&D) expenses were $1,102,371 , reflecting continued advancement of AI-powered drug candidates.
- General and administrative (G&A) expenses were $539,174 including investor & public relations and exchange-related fees.
- Cash and cash equivalents as at September 30, 2025 were $822,293 .
"Over the past several months, Rakovina Therapeutics has delivered a series of meaningful scientific and corporate milestones that underscore the strength of our AI-enabled DDR pipeline and the growing global interest in our programs," stated Jeffrey Bacha, Rakovina Therapeutics executive chairman. "From compelling CNS-penetrant ATR data at AACR-NCI-EORTC to multiple presentations at the Society for Neuro-Oncology Annual Meeting, together with increased visibility at leading investor and industry conferences and the advancement of strategic collaborations such as our NanoPalm joint-venture initiative, we are entering 2026 with significant momentum. These achievements not only validate the depth of our science but also position the company for the next phase of growth as we work to bring transformative therapies to patients in need."
Recent Corporate Highlights
- On November 24, 2025, the Company announced the presentation of two scientific posters at the 2025 Society for Neuro-Oncology Annual Meeting in Honolulu, Hawaii. The posters provided updates on the Company's ATR and PARP1 programs, including compelling preclinical data from the ATR program. Rakovina's lead ATR compounds have now been confirmed as dual ATR/mTOR inhibitors and demonstrate properties highly relevant to treatment-resistant, PTEN-deficient solid tumors, where PTEN loss is one of the most common genetic alterations across cancers and is strongly associated with a high incidence of brain metastases.
- On November 18, 2025, the Company announced that its President & CSO, Prof. Mads Daugaard, has been invited to present and participate as a panelist at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit in January 2026, where he will highlight the Company's AI-enabled DDR drug discovery programs and ongoing preclinical progress.
- On October 27, 2025, the Company announced the presentation of new pre-clinical data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics confirming that its AI-discovered ATR inhibitor program (kt-5000 series) achieved potent ATR inhibition and demonstrated confirmed CNS penetration — a milestone differentiator in the DDR inhibitor space.
- On September 4, 2025, the Company announced that senior management would attend the H.C. Wainwright 27th Annual Global Investment Conference (September 8–10, New York), to engage with investors and potential pharmaceutical partners to discuss the company's AI-enabled oncology pipeline, corporate strategy, and upcoming milestones.
- On August 26, 2025, the Company announced that our president & CSO, Prof. Mads Daugaard, was invited to speak at the 13th Tuscany Retreat on Cancer Research & Apoptosis (August 23–30), highlighting Rakovina Therapeutics DDR-targeted drug discovery and development accomplishments.
- On August 12, 2025, the Company announced that Rakovina Therapeutics and NanoPalm Ltd. announced a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies — beginning with the dual PARP-HDAC inhibitor KT-3283 delivered via NanoPalm's proprietary patterned lipid nanoparticle (pLNP) system — combining Rakovina's drug candidates and validation data with NanoPalm's nanoparticle platform, manufacturing capabilities, and support infrastructure under a Saudi Arabia-based JV with global development and commercialization rights.
- On July 28, 2025, the Company granted an aggregate of 540,000 stock options to certain directors, officers, employees, and consultants pursuant to its Long-Term Incentive Plan . Each option is exercisable at a price of $0.70 per share for a period of five years and vests in equal installments every six months over three years.
- On July 15, 2025, the Company announced that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC).
Selected Financial Results for Q3 2025:
| Sept. 30, 2025 | Dec 31, 2024 | |||||
| $ | $ | |||||
| Cash and Cash Equivalents | 822,293 | 1,312,743 | ||||
| Working Capital deficit | (489,279 | ) | 321,442 | |||
| Intangible Assets | 3,576,493 | 3,977,473 | ||||
| Total Assets | 5,267,709 | 6,240,920 | ||||
| Total Liabilities | 3,380,019 | 1,942,005 | ||||
| Deficit | (21,785,345 | ) | (14,997,929 | ) | ||
Statement of Loss and Comprehensive Loss – Q3 Three months ended September 30
| Sept. 30, 2025 | Sept. 30, 2024 | |||
| $ | $ | |||
| Research & Development | 1,102,371 | 676,200 | ||
| General and Administrative | 539,174 | 266,920 | ||
| Net loss and comprehensive loss | (1,781,757) | (1,011,141) | ||
| Basic and diluted loss per share | (0.08) | (0.11) | ||
| Weighted average shares outstanding | 21,148,038 (post) | 8,966,762 (post) | ||
Rakovina Therapeutics' financial statements as filed with SEDAR can be accessed from the Company's website at: https://www.rakovinatherapeutics.com/corporate-profile/
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Further information may be found at www.rakovinatherapeutics.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Notice Regarding Rakovina Therapeutics Forward-Looking Statements:
This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans," "is expected," "expects," "scheduled," "intends," "contemplates," "anticipates," "believes," "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may," "could," "would," "might," or "will" be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.
Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed, except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at www.sedar.com.
For Further Information Contact:
Michelle Seltenrich, BSc, MBA
Director, Corporate Development
IR@rakovinatherapeutics.com
778-773-5432
